There is considerable evidence for a Hh-driven mechanism of TKI resistance; high plasma levels of Shh in NSCLC patients with advanced disease correlates with poor objective response to several TKI therapies and a reduction in progression-free survival (210 vs. 342 days) (Takam Kamga et al., 2021). Here, SHH is linked to non-small cell lung carcinoma.